Cost-effectiveness analysis of pembrolizumab compared to standard of care as first line treatment for patients with advanced melanoma in Hong Kong
Herbert H. Loong
◽
Carlos K. H. Wong
◽
Linda K. S. Leung
◽
S. C. Tan
◽
Jason Jen
◽
...
2015 ◽
Vol 18
(7)
◽
pp. A460
◽
J Vargas-Valencia
◽
J Garcia Perlaza
2017 ◽
Vol 20
(6)
◽
pp. 574-584
◽
Fernando Rivera
◽
Manuel Valladares
◽
Salvador Gea
◽
Noemí López-Martínez
2016 ◽
Vol 19
(3)
◽
pp. A153
2018 ◽
Vol 29
(8)
◽
pp. 1221-1221
2019 ◽
Vol 94
◽
pp. 80-85
◽
Xudong Chen
◽
Weiting Liang
◽
Ning Wan
◽
Li Zhang
◽
Yunpeng Yang
◽
...
2015 ◽
Vol 18
(7)
◽
pp. A446
◽
T Piha
◽
D Barbosa
◽
L Fahham
1996 ◽
Vol 78
(11)
◽
pp. 2366-2373
◽
Andrea Messori
◽
Sabrina Trippoli
◽
Paola Becagli
◽
Enrico Tendi
2004 ◽
Vol 9
(4)
◽
pp. 153-162
◽
Mickael Löthgren
◽
Michiel Hemels
◽
Clément François
◽
Bengt Jönsson
2017 ◽
Vol 12
(10)
◽
pp. 1496-1502
◽
Christos Chouaid
◽
Laura Luciani
◽
Katell LeLay
◽
Pascal Do
◽
Jaafar Bennouna
◽
...
2020 ◽
Vol 22
◽
pp. S7-S8
J. Cui
◽
X. Zhang
◽
S. Qu
◽
Y. Liu
◽
C. Ye
◽
...